Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:44 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:44 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
Ocular Therapeutix (OCUL) Enters Oversold Territory
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on a bit of a cold streak lately
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on the move lately as the stock has risen by 38% in the past four weeks, and it is currently trading well above its 20-Day SMA
Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
by Zacks Equity Research
Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.